Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria

Mihir Shukla, Chinyere Okpara, Elaine Xiang, Maher Abdul Hay, Shella Saint Fleur-Lominy, Jun Han Choi

Blood (2024) 144 (Supplement 1): 4602.

https://doi.org/10.1182/blood-2024-206504

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

Elias Jabbour, Gerhard Zugmaier, Pilar Martinez Sanchez, Jose J. Rifon, Vaibhav Agrawal, Ryan D Cassaday, Thomas Cluzeau, Françoise Huguet, Vladan Vucinic, Boris Böll, Anita W. Rijneveld, Mar Tormo, Maher Abdul-Hay, Paul R Gordon, Alessandro Rambaldi, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2024-205662

Published: 2024

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

A Samer Al-Homsi, Frank Cirrone, Kelli Cole, Jaime Andres Suarez-Londono, Sharon L. Gardner, Jingmei Hsu, Stephanie Wo, Kelsey Stocker, Benedetto Bruno, Judith Goldberg, Benjamin Levinson, Maher Abdul-Hay

Blood (2022) 140 (Supplement 1): 7628–7630.

https://doi.org/10.1182/blood-2022-162634

Published: 2022

Journal Articles

Evaluating the Safety of Outpatient Ramp up of Venetoclax in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Elaine Xiang, Frank Cirrone, Jamie Chin, Meredith Akerman, Shella Saint Fleur-Lominy, Maher Abdul Hay

Blood (2021) 138 (Supplement 1): 2311.

https://doi.org/10.1182/blood-2021-145057

Published: 2021

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation

Benedetto Bruno, Frank Cirrone, Kelli Cole, Kelsey Stocker, Maher Abdul-Hay, J Andres Suarez-Londono, Tsivia Hochman, Judith Goldberg, A Samer Samer Al-Homsi

Blood (2021) 138 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2021-151809

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

A Samer Samer Al-Homsi, Frank Cirrone, Kelli Cole, Kelsey Stocker, Benedetto Bruno, J Andres Suarez-Londono, Judith Goldberg, Maher Abdul-Hay

Blood (2021) 138 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2021-150856

Published: 2021

Journal Articles

Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study

Wendy Stock, Jae H Park, Ashkan Emadi, Maher Abdul-Hay, Ryan D. Cassaday, Vinod A. Pullarkat, Jonathan Webster, Shuchi S. Pandya, Mark J Mogul, Yelena Shvenke, Jian J Zhu, Adrien Tessier, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2021-149463

Published: 2021

Journal Articles

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Jun H Choi, MD, Jacques Azzi, MD, Tsivia Hochman, MS, Mary Lynn R. Nierodzik, MD, Shella Saint Fleur-Lominy, MD PhD, Maher Abdul Hay, MD

Blood (2019) 134 (Supplement_1): 5067.

https://doi.org/10.1182/blood-2019-129041

Published: 2019

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

Analysis of the IgA Heavy Chain Repertoire in Multiple Myeloma: Implications for Host-Microbiome Influences

Marc Braunstein, MD PhD, Hanane El Bannoudi, PhD, Maher Abdul Hay, MD, Sergei L.K. Pond, PhD, Gregg J. Silverman, MD

Blood (2017) 130 (Supplement 1): 3033.

https://doi.org/10.1182/blood.V130.Suppl_1.3033.3033

Published: 2017

Journal Articles

Sensitivity to Romidepsin Cytotoxicity Depends on STAT3-Dependent Metabolic Reprogramming of Cancer Cells

Maher Abdul-Hay, MD, Daniel Gough, PhD, David Levy, PhD

Blood (2014) 124 (21): 3599.

https://doi.org/10.1182/blood.V124.21.3599.3599

Published: 2014

Journal Articles

The MDS-Associated Protein EVI1 Impairs Erythroid and Megakaryocytic Differentiation by Direct Interaction with GATA-1.

Leopoldo Laricchia-Robbio, PhD, Donglan Li, MD, PhD, Raffaella Fazzina, Soumen Chakraborty, PhD, Maher Abdul Hay, MD, Giuseppina Nucifora, PhD

Blood (2005) 106 (11): 3007.

https://doi.org/10.1182/blood.V106.11.3007.3007

Published: 2005

NARROW

A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Evaluating the Safety of Outpatient Ramp up of Venetoclax in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation

Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Analysis of the IgA Heavy Chain Repertoire in Multiple Myeloma: Implications for Host-Microbiome Influences

Sensitivity to Romidepsin Cytotoxicity Depends on STAT3-Dependent Metabolic Reprogramming of Cancer Cells

The MDS-Associated Protein EVI1 Impairs Erythroid and Megakaryocytic Differentiation by Direct Interaction with GATA-1.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only